NCT05638841 Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation
| NCT ID | NCT05638841 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-01-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2023-01-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, the continuous inclusion of atrial fibrillation patients treated by catheter ablation in the Department of Cardiology, Peking University Third Hospital, through the collection of clinical data and outpatient follow-up, to explore the risk factors of atrial fibrillation recurrence after catheter ablation and the influencing factors of major clinical events in atrial fibrillation patients, and further guide the management mode of atrial fibrillation patients.
Eligibility Criteria
Inclusion Criteria: * 1\) Age \> 18 * 2\) ECG or holter electrocardiogram confirmed atrial fibrillation Exclusion Criteria: * 1\) Hematological diseases, autoimmune diseases and malignant tumors * 2\) Immobility caused by hemiplegia or severe trauma * 3\) The expected survival time is less than 2 years * 4\) Poor compliance and high risk of expected loss of follow-up * 5\) Disorders of consciousness or Alzheimer's disease
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05638841 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05638841 currently recruiting?
Yes, NCT05638841 is actively recruiting participants. Contact the research team at liyanguangsuper@163.com for enrollment information.
Where is the NCT05638841 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05638841 clinical trial?
NCT05638841 is sponsored by Peking University Third Hospital. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.